Article citationsMore>>

Floch, M.H., Walker, W.A., Sanders, M.E., Nieuwdorp, M., Kim, A.S., Brenner, D.A., Qamar, A.A., Miloh, T.A., Guarino, A., Guslandi, M., Dieleman, L.A., Ringel, Y., Quigley, E.M. and Brandt, L.J. (2015) Recommendations for Probiotic Use-2015 Update: Proceedings and Consensus Opinion. Journal of Clinical Gastroenterology, 49, S69-S73.
https://doi.org/10.1097/mcg.0000000000000420

has been cited by the following article:

• TITLE: Use of the Multispecies Probiotic Winclove 500/BactoSan pro FOS Leads to Less Gastrointestinal Complaints in Adults—An Observational In Vivo Pilot Study

  AUTHORS: Fritz Grossenbacher, Agim Gashi, Isolde Besseling-van der Vaart

  KEYWORDS: Probiotics, Healthy Volunteers, Gut Health, Quality of Life and Abdominal Pain

  JOURNAL NAME: Advances in Microbiology, Vol.6 No.14, December 7, 2016

  ABSTRACT: The potential benefit of probiotics on the gut microbiota and on various gastrointestinal disorders is well documented. It has become clear that these probiotic effects are strain-specific, underlying the necessity for a well-founded strain selection for research and clinical practice. Whether probiotics also have a positive effect on parameters of gastrointestinal function in a healthy population is less investigated. The objective of this in vivo observational study was to investigate the effect of a 6-week intervention with a multispecies probiotic product on gut health and quality of life (QoL) in a population of otherwise healthy adults and to evaluate the feasibility of conducting a controlled trial on probiotic effects in this population. A total of 40 participants from 3 different health centres were included in the study. After a 1-week inclusion phase, participants were supplemented for a 6-week period with Winclove 500/BactoSan pro FOS. During the run-in phase and each week during the observational period, gastrointestinal functional parameters were documented by an adapted version of the Eypasch questionnaire. Data on QoL was collected at baseline and at the end of the intervention period. The total gastrointestinal (GI) symptom score was reduced from 10 (4 - 21) at baseline to 6 (0 - 15) (p